Abstract:OBJECTIVE:To evaluate the value of real time quantitative RT-PCR (Q-PCR) for monitoring bcr-abl mRNA levels in chronic myeloid leukemia (CML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT).METHODS:Quantification of bcr-abl mRNA was performed on 316 bone marrow samples from 112 patients with CML after HSCT by Q-PCR using the TaqMan probe system. The bcr-abl mRNA level was normalized by control gene abl. Cytogenetic response was evaluated with fluorescent in-situ hybridization (FISH).RESULTS:The reproducible sensitivity of Q-PCR was 5 copies. The coefficients C(T) of interassay and intraassay variation for abl and bcr-abl were all below 2.0%. 289 bone marrow samples were collected from 101 CML patients who achieved a sustained complete cytogenetic response (CCyR) one month post allo-HSCT in a period of 6 - 60 months (median 12 months) at different intervals. In general, the median bcr-abl levels gradually decreased with the prolongation of time after HSCT: the median bcr-abl levels were 0.035% (0 - 0.406%) at 1 month post allo-HSCT (+ 1 month), 0.006% (0 - 0.683%) at +3 month, 0% (0 - 0.225%) at +6 month and remained 0% till +24 months. The highest level in CCyR patients detected at + 6 month was 0.068%. The bcr-abl mRNA level was decreased by 3 log in sustained CCyR patients at + 1 month compared with the newly diagnosed CML-CP patients (33.0%, data unpublished). On the contrary, Q-PCR results ranged from 0.12% to 13.45% in 8 cytogenetic non-responders or relapsed patients post allo-HSCT. Among them, 5 patients' samples were collected 1 - 2 months before cytogenetic relapse, the results were ranged from 0.09% to 3.42%. If 0.09% was assumed 0.09% as a threshold, 9 sustained CCyR patients (8.9%) were tested once higher than that within 6 month after HSCT but decreased to 0% eventually. 2 blast crisis patients achieved CCyR within 1.6 and 3 months after HSCT, but hematological relapse occurred after 1 and 1.5 months, and their bcr-abl mRNA levels increased dramatically from 0% and 0.14% to 46.9% and 75.9% respectively.CONCLUSIONS:Q- PCR is a sensitive, precise and reliable technique, and can be used to monitor CML patients post allo-HSCT regularly. Patients in blast phase of CML should be monitored more frequently.

Assessment of Standardization and International Scale (IS) Alignment Efforts of BCR-ABL1 Testing by the Chinese CML Alliance in an International External Quality Assessment Program

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

[Monitoring Bcr-Abl Mrna Levels by Real-Time Quantitative RT-PCR in Chronic Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation].

[A Multicenter Study on the Revalidation of Validated Conversion Factor for the Conversion of BCRABL（P210）transcript Levels to the International Scale in Chronic Myeloid Leukemia].

New Practice of BCR::ABL1 Standardization System Based on P210 and P190 BCR::ABL1 Reference Materials.

Comparative analysis of BCR::ABL1 p210 mRNA transcript quantification and ratio to ABL1 control gene converted to the International Scale by chip digital PCR and droplet digital PCR for monitoring patients with chronic myeloid leukemia

Quantitative detection of BCR–ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment

The Establishment and Application of Internal Quality Control System for Real-Time Quantitative PCR Detection of BCR-ABL (P210) Transcript Levels

[Monitoring Bcr/abl Mrna Levels in Imatinib Mesylate Treated Chronic Myeloid Leukemia Patients by Real-Time Quantitative RT-PCR].

Real-time Quantitative PCR Monitoring of Minimal Residual Disease in CML after Treatment

THE DIFFERENCES AND CORRELATIONS OF BCR-ABL TRANSCRIPTS BETWEEN PERIPHERAL BLOOD AND BONE MARROW ASSAYS ARE ASSOCIATED WITH THE MOLECULAR RESPONSES IN THE BONE MARROW FOR CHRONIC MYELOGENOUS LEUKEMIA

Expression and significance of BCR-ABL mRNA in chronic myeloid leukemia patients by qPCR

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

A multicenter comparison study on the quantitative detection of bcr-abl (P210) transcript levels in China]

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK